A share price of Regulus Therapeutics Inc [RGLS] is currently trading at $1.64, up 7.19%. It is a good measure of the stock’s recent performance to check whether the stock’s short-term value is rising or falling. The RGLS shares have gain 17.14% over the last week, with a monthly amount glided 1.86%, and seem to be holding up well over a long-time horizon.
3 Tiny Stocks Primed to Explode
The world's greatest investor — Warren Buffett — has a simple formula for making big money in the markets. He buys up valuable assets when they are very cheap. For stock market investors that means buying up cheap small cap stocks like these with huge upside potential.
We've set up an alert service to help smart investors take full advantage of the small cap stocks primed for big returns.
Click here for full details and to join for free
Sponsored
From an analyst’s perspective:
Regulus Therapeutics Inc [NASDAQ: RGLS] stock has seen the most recent analyst activity on August 02, 2024, when Oppenheimer initiated its Outperform rating and assigned the stock a price target of $7. Previously, Leerink Partners started tracking the stock with Outperform rating on March 18, 2024, and set its price target to $6. On March 28, 2018, B. Riley FBR Inc. initiated with a Neutral rating and assigned a price target of $1 on the stock. Leerink Partners started tracking the stock assigning a Outperform rating and suggested a price target of $2 on January 05, 2018. Chardan Capital Markets reiterated its recommendation of a Buy and reduced its price target to $2.50 on June 13, 2017. Wedbush reiterated a Outperform rating for this stock on March 06, 2017, and downed its price target to $6. In a note dated January 30, 2017, Wells Fargo downgraded an Market Perform rating on this stock.
Regulus Therapeutics Inc experienced fluctuations in its stock price throughout the past year between $1.08 and $3.79. Regulus Therapeutics Inc [NASDAQ: RGLS] shares were valued at $1.64 at the most recent close of the market.
Analyzing the RGLS fundamentals
Gross Profit Margin for this corporation currently stands at 0.19% with Operating Profit Margin at -147.67%, Pretax Profit Margin comes in at -137.84%, and Net Profit Margin reading is -137.84%. To continue investigating profitability, this company’s Return on Assets is posted at -0.44, Equity is -0.53 and Total Capital is -0.51. An extended analysis of the company’s primary financial structure reveals a debt-to-equity ratio of0.01.
Before buying any particular stock, readers tend to pay close attention to the indicators that support and create resistance. The company’s stock is currently sitting at 1.5550 points at the first support level, and at 1.4700 for the second support level. However, for the 1st resistance point, the stock is sitting at 1.6900, and for the 2nd resistance point, it is at 1.7400.
Ratios To Look Out For
To put it in perspective, the Current Ratio for Regulus Therapeutics Inc [NASDAQ:RGLS] is 13.65. Further, the Quick Ratio stands at 13.65, while the Cash Ratio is 4.07.
Transactions by insiders
Recent insider trading involved Collier Kathryn J, Director, that happened on Jul 25 ’24 when 4000.0 shares were purchased. Chief Financial Officer, CALSADA CRISPINA completed a deal on Jan 18 ’24 to sell 5468.0 shares. Meanwhile, Sr. VP & General Counsel Aker Christopher Ray sold 5468.0 shares on Jan 18 ’24.
